These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7405235)

  • 21. Plasma elimination of cardiac troponin I in end-stage renal disease.
    Ellis K; Dreisbach AW; Lertora JL
    South Med J; 2001 Oct; 94(10):993-6. PubMed ID: 11702827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of uremia.
    Dienst SG; Morris B
    J Maine Med Assoc; 1966 Jan; 57(1):2-4. PubMed ID: 5902806
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man.
    Koopman-Kimenai PM; Vree TB; Booij LH; Dirksen R; Nijhuis GM
    Eur J Anaesthesiol; 1993 Mar; 10(2):125-32. PubMed ID: 8462537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Importance and limitations of metabolic drug half-life].
    Buclin T; Biollaz J
    Praxis (Bern 1994); 1997 Oct; 86(43):1693-7. PubMed ID: 9432694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single dose intravenous pharmacokinetics of fluconazole in infants.
    Krzeska I; Yeates RA; Pfaff G
    Drugs Exp Clin Res; 1993; 19(6):267-71. PubMed ID: 8013270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency.
    Catalina PF; Páramo C; Andrade MA; Mallo F
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):341-7. PubMed ID: 17302866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 131I effective half-life (Teff) for patients with thyroid cancer.
    Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
    Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Changes in lipid and carbohydrate metabolism in chronic uremia].
    Alarcón Zurita A; Pizá C; Riesco M; Mora M; Marco J; Morey A; Bestard J; Ballesteros JA; De La Calle F
    Rev Clin Esp; 1981 Mar; 160(6):377-80. PubMed ID: 7255802
    [No Abstract]   [Full Text] [Related]  

  • 30. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

  • 31. Harnessing transporters to clear uremic toxins.
    Moe OW
    J Am Soc Nephrol; 2009 Dec; 20(12):2483-4. PubMed ID: 19926890
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The distribution and irreversible tissue binding of practolol and its metabolites in the hamster [proceedings].
    Lindup WE; Longshaw S; Orton TC; Whittaker SE
    Br J Pharmacol; 1979 Jul; 66(3):504P. PubMed ID: 526773
    [No Abstract]   [Full Text] [Related]  

  • 34. Does ampicillin affect practolol kinetics? [proceedings].
    Kelly JG; Leahey WJ; McDevitt DG; Riddell JG
    Br J Clin Pharmacol; 1977 Jun; 4(3):396P. PubMed ID: 901722
    [No Abstract]   [Full Text] [Related]  

  • 35. [Mechanisms of carbohydrate and lipid metabolism disorders in patients with terminal uremia].
    Kriachko AA; Ermolenko VM; Trikashnyĭ AA; Tatsievskiĭ VA
    Vestn Akad Med Nauk SSSR; 1980; (6):17-22. PubMed ID: 7405374
    [No Abstract]   [Full Text] [Related]  

  • 36. Utilization of tyrosine-containing dipeptides and N-acetyl-tyrosine in hepatic failure.
    Druml W; Hübl W; Roth E; Lochs H
    Hepatology; 1995 Apr; 21(4):923-8. PubMed ID: 7705801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differences between the glomerular filtration rate estimated by the MDRD equation and the measurement of creatinine and urea clearance in unselected patients with terminal renal insufficiency].
    Caravaca F; Arrobas M; Luna E; Naranjo M; Pizarro JL; Sánchez-Casado E
    Nefrologia; 2002; 22(5):432-7. PubMed ID: 12497744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of guanidino compounds in uremia (author's transl)].
    Kadono K; Kokawa M; Irie A; Kushiro H; Kodama J; Kimura G; Satani M; Hayashi C
    Rinsho Byori; 1980 Jul; 28(7):660-4. PubMed ID: 7463759
    [No Abstract]   [Full Text] [Related]  

  • 40. Anxiolytics and sedatives and risk of fractures: effects of half-life.
    Vestergaard P; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2008 Jan; 82(1):34-43. PubMed ID: 18175030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.